United Therapeutics(US:UTHR)2023-11-01 21:36Financial Performance - United Therapeutics reported total revenue of $609 million, an 18% increase year-over-year[19, 53] - Tyvaso (DPI and Nebulized) revenue reached $326 million, a 26% increase year-over-year[19, 53] - Remodulin revenue increased by 15% year-over-year to $131 million[19, 53] - Orenitram revenue increased by 5% year-over-year to $92 million, marking the second-highest revenue quarter for the product[19, 53, 57] - Unituxin revenue increased by 11% year-over-year to $51 million[19, 53] - The company's TTM (trailing twelve months) operating cash flow was $956 million[19] - United Therapeutics holds $4.9 billion in cash, cash equivalents, and marketable investments[19] Clinical Development & Pipeline - Enrollment is progressing in the TETON 1 and 2 studies for Tyvaso in Idiopathic Pulmonary Fibrosis (IPF), with approximately 60% and 50% enrollment, respectively, as of October 9, 2023[25] - The TETON PPF study for Tyvaso in Progressive Pulmonary Fibrosis (PPF) has enrolled its first patient in October 2023[27, 31] - The ADVANCE OUTCOMES study for Ralinepag in Pulmonary Arterial Hypertension (PAH) has enrolled over 510 patients as of October 1, 2023[37] Organ Manufacturing - United Therapeutics completed the acquisition of IVIVA Medical for $50 million, with a 2% royalty on any commercial sales[42] - The company anticipates the last xenokidney transplant in early 2024 and expects animal introduction in the first half of 2024 at the Designated Pathogen Free Facility (DPF)[45] - United Therapeutics has invested approximately $75 million in its Christiansburg, VA facility for xenotransplantation efforts, with construction completed in Q4/23[47]